Plain-English translation of NCT07293468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tests two different radiation therapy approaches—one using traditional focused radiation (SBRT) and one using radioactive beads (Y90 SIRT)—both combined with immunotherapy, to treat large, advanced liver cancers that cannot be surgically removed. Researchers want to see which approach works better and helps patients live longer. This study will enroll about 106 patients and compare how effective these two treatment combinations are.
Most people with large, advanced liver cancer don't have many good treatment options, and current standard treatments have poor outcomes. This trial exists to find a better way to treat these tumors by combining radiation therapy with immunotherapy, which may help the body's immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive one of two treatment approaches: either a combination of traditional focused radiation therapy plus immunotherapy, or radioactive bead radiation therapy plus immunotherapy. Over several months, you will receive multiple treatments at the hospital, along with regular blood tests and imaging scans to monitor how well the treatment is working and to watch for any side effects. Your doctors will carefully track your progress and adjust your care as needed.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Hong Kong